|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 成人缺血性卒中早期处理指南显示文摘本指南旨在对成年急性缺血性卒中患者评价和治疗各要素的现有证据做一回顾。目标读者是那些为发病后48h内的卒中患者提供治疗的内科医生和其他急诊医疗保健人员。另外,也包括向医疗保健政策制定者提供的信息。方法:专家小组成员由美国心脏协会(AHA)卒中委员会科学声明监督委员会任命,他们代表了来自不同领域的专家。专家小组以2003年后发表的报道为重点,对相关文献进行回顾,采用AHA卒中委员会的证据水平分级标准对证据进行分级并做出推荐。本声明经专家小组认可后,再由AHA科学顾问和协调委员会进行同行评议和正式批准。本指南打算在3年内做全面更新。结果:对急性缺血性卒中患者的处理仍然是多方面的,包括尚未在临床试验中进行过验证的一些医疗诊治方面。本声明包括从急诊医疗服务人员开始接触患者到入院初期处理的推荐意见。静脉重组组织型纤溶酶原激活剂仍然是已得到证实的最有效的卒中急诊治疗干预方法。包括动脉应用溶栓药和机械介入在内的一些方法显示出希望。因为许多推荐是在有限的证据基础上做出的,因此需要对急性缺血性卒中的治疗进行更多的研究。 | Harold P. Adams Gregory del Zoppo Mark J. Alberts Deepak L. Bhatt Lawrence Brass Anthony Furlan Robert L. Grubb Randall T. Higashida Edward C. Jauch Chelsea Kidwell Patrick D. Lyden Lewis B. Morgenstern Adnan I. Qureshi Robert H. Rosenwasser Phillip A. Scott Eelco F.M. Wijdicks 李焰生(译) 熊昕丽(译) 林岩(译) 沈沸(译) 俞羚(译) 邹静(译) 张静芳(译) 孙亚蒙(译) 周洁茹(译) 蒋仙国(译) 陈莺(译) | 2007 | 国际脑血管病杂志2007，15，6： | 18 |
| 2 | Metformin does not improve survival in patients with hepatocellular carcinoma显示文摘AIM:To assess whether metformin,which has a chemopreventive effect in chronic liver disease,has any chemotherapeutic effect in hepatocellular carcinoma.METHODS:This was a retrospective study of 701 patients with newly diagnosed hepatocellular carcinoma(HCC)seen between January 2005 and June 2011 at Mayo Clinic,Rochester,Minnesota.This patient cohort was a part of the global HCC BRIDGE study,which is a large longitudinal study of HCC determining the realworld experience of HCC characteristics,management and patient outcomes.We defined significant metformin exposure as continuation of this agent at least 90d beyond diagnosis of HCC,and compared survival of diabetic patients on metformin to diabetic patients not on metformin and non-diabetics.RESULTS:Our cohort was 72.9%male,with a mean±SD age of 62.6±12.3 years.The most common etiologies of liver disease were hepatitis C(34%),alcoholic liver disease(29%),fatty liver disease(15%)and hepatitis B(9%).By univariate analysis,using diabetics not on metformin as the reference group,diabetic patients with HCC on metformin had no survival advantage,with a HR(95%CI)of 1.0(0.8-1.3).Non-diabetic HCC patients also did not appear to have a survival advantage as compared to diabetic HCC patients not on metformin,as demonstrated by a HR(95%CI)of1.1(0.7-1.7).Diabetics on metformin beyond 90 d after HCC diagnosis had a longer median survival at 34.2 mo,as compared to 25.5 mo among diabetic patients who were not on metformin or had discontinued metformin within 90 d after HCC diagnosis.This finding was likely due to potential survival bias among those who lived long enough to receive metformin.CONCLUSION:Although the literature suggests a chemotherapeutic effect in other malignancies,our study demonstrates no survival benefit to the use of metformin in diabetic patients with HCC. | Mamatha Bhat Roongruedee Chaiteerakij William S Harmsen Cathy D Schleck Ju Dong Yang Nasra H Giama Terry M Therneau Gregory J Gores Lewis R Roberts | 2014 | World Journal of Gastroenterology2014，20，42： | 11 |
| 3 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models显示文摘AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma(HCC) patients after liver transplant.METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein(AFP), Lens culinaris agglutinin-reactive AFP(AFP-L3), and des-gammacarboxyprothrombin(DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios(HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42(1.18-5.00), 1.86(0.98-3.52), and 2.83(1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48(1.15-1.91) and 1.59(1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45(1.06-1.98) and 1.38(1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65,0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant(S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter(S-LAD). | Nicha Wongjarupong Gabriela M Negron-Ocasio Roongruedee Chaiteerakij Benyam D Addissie Essa A Mohamed Kristin C Mara William S Harmsen J Paul Theobald Brian E Peters Joseph G Balsanek Melissa M Ward Nasra H Giama Sudhakar K Venkatesh Denise M Harnois Michael R Charlton Hiroyuki Yamada Alicia Algeciras-Schimnich Melissa R Snyder Terry M Therneau Lewis R Roberts | 2018 | World Journal of Gastroenterology2018，24，12： | 5 |
| 4 | The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets显示文摘 | Ju Dong Yang Ikuo Nakamura Lewis R. Roberts | 2010 | Seminars in Cancer Biology2010，，1： | 4 |
| 5 | Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study显示文摘 | Joong‐Won Park Minshan Chen Massimo Colombo Lewis R. Roberts Myron Schwartz Pei‐Jer Chen Masatoshi Kudo Philip Johnson Samuel Wagner Lucinda S. Orsini Morris Sherman | 2015 | Liver Int2015，，9： | 3 |
| 6 | α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular Carcinoma显示文摘 | Jorge A. Marrero Ziding Feng Yinghui Wang Mindie H. Nguyen Alex S. Befeler Lewis R. Roberts K. Rajender Reddy Denise Harnois Josep M. Llovet Daniel Normolle Jackie Dalhgren David Chia Anna S. Lok Paul D. Wagner Sudhir Srivastava Myron Schwartz | 2009 | Gastroenterology2009，，1： | 3 |
| 7 | ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension显示文摘 | Vallerie V. McLaughlin Stephen L. Archer David B. Badesch Robyn J. Barst Harrison W. Farber Jonathan R. Lindner Michael A. Mathier Michael D. McGoon Myung H. Park Robert S. Rosenson Lewis J. Rubin Victor F. Tapson John Varga | 2009 | Journal of the American College of Cardiology2009，，17： | 2 |
| 8 | Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation显示文摘 | Michael Charlton Edward Gane Michael P. Manns Robert S. Brown Michael P. Curry Paul Y. Kwo Robert J. Fontana Richard Gilroy Lewis Teperman Andrew J. Muir John G. McHutchison William T. Symonds Diana Brainard Brian Kirby Hadas Dvory-Sobol Jill Denning Sara | 2014 | Gastroenterology2014，，： | 2 |
| 9 | The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma显示文摘 | Ruben Bonilla Guerrero Lewis R. Roberts | 2005 | Journal of Hepatology2005，，5： | 2 |
| 10 | Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes显示文摘 | Xiaodan Zhang William S. Harmsen Teresa A. Mettler W. Ray Kim Rosebud O. Roberts Terry M. Therneau Lewis R. Roberts Roongruedee Chaiteerakij | 2014 | Hepatology2014，，6： | 2 |
| 11 | The new liver allocation system: Moving toward evidence-based transplantation policy显示文摘 | Richard B. Freeman Russell H. Wiesner Ann Harper Sue V. McDiarmid Jack Lake Erick Edwards Robert Merion Robert Wolfe Jeremiah Turcotte Lewis Teperman | 2002 | Liver Transplantation2002，，9： | 2 |
| 12 | Prognostic significance of endoluminal ultrasound-defined disease length and tumor volume (EDTV) for patients with the diagnosis of esophageal cancer显示文摘 | Christopher P. Twine S. Ashley Roberts Wyn G. Lewis B. Vicki Dave Claire E. Rawlinson David Chan Mark Robinson Tom D. Crosby | 2010 | Surgical Endoscopy2010，，4： | 2 |
| 13 | Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities显示文摘 | Robert G. Gish Bruce D. Given Ching-Lung Lai Stephen A. Locarnini Johnson Y.N. Lau David L. Lewis Thomas Schluep | 2015 | Antiviral Research2015，，： | 2 |
| 14 | 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations显示文摘 | Jacques Genest Ruth McPherson Jiri Frohlich Todd Anderson Norm Campbell André Carpentier Patrick Couture Robert Dufour George Fodor Gordon A. Francis Steven Grover Milan Gupta Robert A. Hegele David C. Lau Lawrence Leiter Gary F. Lewis Eva Lonn G.B. John | 2009 | Canadian Journal of Cardiology2009，，10： | 2 |
| 15 | Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial显示文摘 | P. Gabriel Steg Robert A. Harrington H?kan Emanuelsson Hugo A. Katus Kenneth W. Mahaffey Bernhard Meier Robert F. Storey Daniel M. Wojdyla Basil S. Lewis Gerald Maurer Lars Wallentin Stefan K. James | 2013 | Circulation2013，，10： | 2 |
| 16 | Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo显示文摘 | Huanjie Shao Chun Gao Haikuo Tang Hao Zhang Lewis R. Roberts Bonnie L. Hylander Elizabeth A. Repasky Wen W. Ma Jingxin Qiu Alex A. Adjei Grace K. Dy Chunrong Yu | 2011 | Journal of Hepatology2011，，1： | 2 |
| 17 | Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma显示文摘 | Ju Dong Yang W. Ray Kim Ritika Coelho Teresa A. Mettler Joanne T. Benson Schuyler O. Sanderson Terry M. Therneau Bohyun Kim Lewis R. Roberts | 2011 | Clinical Gastroenterology and Hepatology2011，，1： | 2 |
| 18 | Dietary Intake of Soy Genistein is Associated with Lung Function in Patients with Asthma显示文摘 | Lewis J Smith Janet T Holbrook Robert Wise | 2004 | Journal of Asthma2004，41，： | 1 |
| 19 | Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial显示文摘 | Benjamin M Scirica Marc P Bonaca Eugene Braunwald Gaetano M De Ferrari Daniel Isaza Basil S Lewis Felix Mehrhof Piera A Merlini Sabina A Murphy Marc S Sabatine Michal Tendera Frans Van de Werf Robert Wilcox David A Morrow | 2012 | The Lancet . 2012 (9850)2012，，9850： | 1 |
| 20 | A Globally Convergent Augmented Lagrangian Pattern Search Algorithm for Optimization with General Constraints and Simple Bounds 显示文摘 | Lewis Robert Michael and Virginia Torczon | 2002 | SIAM Journal on Optimization2002，12，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员